ALLERGYSTOPNew Supplement on Nutritional Status in Children with Food Allergy
Food supplement
+ Placebo
Food Hypersensitivity+1
+ Hypersensitivity
+ Hypersensitivity, Immediate
Treatment Study
Summary
Study start date: December 30, 2024
Actual date on which the first participant was enrolled.This study focuses on evaluating a new supplement to help improve the nutritional status of children with food allergies. Food allergies are becoming more common, especially among young children, and are often challenging due to the need to avoid certain foods. This avoidance can lead to issues like poor growth and lack of essential nutrients. Since there is no FDA-approved treatment for food allergies, this study aims to find alternative ways to manage the nutritional challenges these children face, potentially offering better health outcomes and reducing the impact of strict dietary restrictions. In this study, children with food allergies will receive a new supplement. The children will be monitored to see if the supplement helps improve their nutritional status, which could involve assessing their growth, nutrient levels, and overall health. By measuring these factors, researchers hope to determine if the supplement can offer a beneficial alternative to current dietary management practices. There is no mention of specific risks or benefits in the study details, but the goal is to provide a safer and more effective way to support the nutritional needs of children with food allergies.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.30 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 36 to 60 Months
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Department of Traslational Medical Science - University of Naples Federico II
Naples, ItalyOpen Department of Traslational Medical Science - University of Naples Federico II in Google Maps